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BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical
behaviour of colon cancers than does EGFR expression. However, the prognostic effect of phospho-EGFR in primary colon cancer
remains undefined.
METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of
TNM stage II and III colon cancers from completed adjuvant therapy trials (n¼388). Staining intensity was scored and correlated with
clinicopathological variables, DNA mismatch repair (MMR) status, rates of cell proliferation (Ki-67), apoptosis (caspase-3), and patient
survival.
RESULTS: Phospho-EGFR expression was detected in 157 of 388 (40%) tumours, whereas EGFR was found in 214 of 361 (59%).
Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour
stage (P¼0.03). Tumours overexpressing EGFR (P¼0.0002) or phospho-EGFR (P¼0.015) showed increased Ki-67, but not
caspase-3 expression. Phospho-EGFR was not prognostic. EGFR intensity was associated with worse disease-free survival (DFS)
(hazard ratio (HR): 1.21 (1.03, 1.41); P¼0.019) and overall survival (OS) (HR: 1.19 (1.02, 1.39); P¼0.028). Tumours expressing both
EGFR and phospho-EGFR had similar survival as EGFR alone. Stage and lymph node number were prognostic for DFS and OS, and
histological grade for OS. EGFR was an independent predictor of DFS (P¼0.042) after adjustment for stage, histological grade, age,
and MMR status.
CONCLUSION: Phospho-EGFR and EGFR expression were associated with tumour cell hyperproliferation. Phospho-EGFR was not
prognostic, whereas increased EGFR intensity was independently associated with poor DFS.
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The epidermal growth factor receptor (EGFR) is a transmembrane
glycoprotein and receptor tyrosine kinase (TK) that is encoded by
the c-erbB-1 proto-oncogene (Yarden and Sliwkowski, 2001). EGFR
signalling is activated by ligands that induce homo- or hetero-
dimerisation with other ErbB family members (Yarden and
Sliwkowski, 2001). Binding of a ligand to the extracellular domain
of EGFR results in receptor dimerisation and autophosphorylation
on tyrosine residues with the major phosphorylation site being
tyrosine 1173 (Tyr-1173) (Lombardo et al, 1995; Chattopadhyay
et al, 1999). EGFR activation triggers intracellular signalling that
results in increased proliferation and a number of processes
related to cell survival (Yarden and Sliwkowski, 2001; Buettner
et al, 2002). EGFR expression is implicated in the pathogenesis of
colorectal cancer (Roberts et al, 2002) and a direct relationship
between EGFR expression by colon cancer cells and their ability to
produce hepatic metastasis has been shown in preclinical models
(Radinsky et al, 1995).
Evidence suggests that EGFR-activation status may be more
important than receptor expression (Piazzi et al, 2006). However,
only limited data exist for phospho-EGFR in human colorectal
cancers and highly variable expression frequencies were reported
using an anti-Tyr 1068 antibody (Cunningham et al, 2005;
Personeni et al, 2005). Till date, the prognostic effect of
phospho-EGFR expression in human colon cancers has not been
addressed. A polymorphism in the EGFR gene (R497K) was
associated with a marked decrease in EGFR phosphorylation and
was reported to be a favourable prognostic marker in stage II/III
colorectal cancers (Wang et al, 2007). In contrast to phospho-
EGFR, EGFR expression in primary colon cancers has been shown
to be an adverse prognostic marker in some (Lee et al, 2002;
Resnick et al, 2004), but not other (McKay et al, 2002; Spano et al,
2005), studies and an evaluation of its prognostic effect using the
FDA-approved antibody and methodology is lacking.
Recently, elongation of a microsatellite repeat at the 50
untranslated region (UTR) was found in colon cancers with
microsatellite instability (MSI), but not in microsatellite stable
tumours (Baranovskaya et al, 2009). Elongation of this repeat was
shown to result in the downregulation of EGFR mRNA levels
in human colon cancer cells and in human tumours with MSI.
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levels in relation to MSI status. MSI results from defective
DNA mismatch repair (MMR) and these tumours show distinct
phenotypic features and are reported to have better stage-adjusted
survival rates compared with tumours with intact MMR (Sinicrope
and Sargent, 2009).
In this report, we determined the prognostic effect of EGFR
expression in relation to its activation status in primary stage II
and III colon carcinomas from patients treated in 5-fluorouracil-
based adjuvant therapy trials. We utilised antibodies against the
major EGFR phosphorylation site Tyr-1173 and utilised the EGFR
pharmDx kit. The association of EGFR with DNA MMR status, and
phospho-EGFR or EGFR expression with cell proliferation and/or
apoptosis were also studied.
MATERIALS AND METHODS
Patients and specimens
Surgically resected, primary colon carcinomas were analysed from
patients who participated in randomized 5-fluorouracil-based
adjuvant chemotherapy trials conducted by the North Central
Cancer Treatment Group (NCCTG: 91-46-53, 79-46-04, 89-46-51).
Details of these studies have been previously reported (Allegra
et al, 2002; O’Connell et al, 2006). Paraffin-embedded tumour
blocks were available from a non-random patient subset of the
overall study populations. Phospho-EGFR was analysed in 388
patients with TNM stage II and III colon carcinomas. EGFR was
studied in 303 stage II and III cases from a single adjuvant trial
(91-46-53). Tumour histological grade was categorized as: grade 1,
well differentiated; grade 2, moderately differentiated; grade 3,
poorly differentiated; and grade 4, undifferentiated (Compton
et al, 2000).
All patients were censored at 5 years after randomisation for
disease-free survival (DFS) and were followed for a median of 8
years for overall survival (OS).
Tissue microarrays (TMA)
Tissue microarrays had been constructed from paraffin tumour
blocks (Beecher Instruments, Silver Spring, MD, USA). Each patient
had three tumour cores and two normal cores consisting of normal
liver, tonsil or placenta that were used as Immunohistochemistry
(IHC) controls and navigation markers (Jourdan et al,2 0 0 3 ) .T i s s u e
sections (4–6mm) were cut from TMA blocks for IHC.
Immunohistochemistry
Slides were deparaffinized, endogenous peroxidase activity was
blocked and staining was carried out using a DAKO Cytomation
Autostainer (DAKO, Carpinteria, CA, USA). For phospho-EGFR,
heat-induced epitope retrieval was carried out in EDTA using a
steamer (30min, 98–1001C). Slides were placed into a wash buffer
(Tris-buffered saline solution containing 0.05% Tween 20, pH 7.6
(DAKO)) and then a serum-free protein block was applied (DAKO)
for 10min. After rinsing in wash buffer, slides were incubated
overnight at 41C with the anti-phospho-EGFR (Tyr-1173) mouse
monoclonal antibody (DAKO), diluted 1:100. After rinsing, a
secondary antibody system (advance HRP (DAKO)) was applied
for 15min. For EGFR, non-specific antibody binding was inhibited
using a protein block BACKGROUNDSNIPER (Biocare Medical,
Walnut Creek, CA, USA). Slides were stained for EGFR using the
Dako pharmDx kit (DAKO) as per the manufacturer’s instructions.
Colour was developed using diaminobenzidine followed by
counterstaining with hematoxylin. For both antibodies, a breast
carcinoma was used as a positive control and a negative control
omitted the primary antibody but included all other steps.
For the analysis of Ki-67 and caspase-3, antigen retrieval was
carried out using a heat-inactivated epitope retrieval system,
EDTADECLOAKER (Biocare). Double staining for caspase-3 and
Ki-67 was carried out by incubating sections in a prediluted
monoclonal and polyclonal antibody double stain cocktail,
Ki-67(M)þcaspase-3(R) (Biocare) for 60min. Slides were then
incubated with MACH 2 (HRP(ms)þALP(rb)) secondary anti-
body cocktail (Biocare) for 30min. Next, sections were incubated
in Cardassian DAB (HRP) to visualise Ki-67 and in Vulcan Fast
Red (ALP) to visualise caspase-3 (both reagents from Biocare).
Slides were counterstained in hematoxylin.
IHC scoring
Phospho-EGFR was scored as having either weak/moderate (1þ
and 2þ) or absent staining intensity in the tumour cytoplasm.
Membranous EGFR staining was scored as per the manufacturer’s
instructions (Guidelines for Interpreting EGFR pharmDx, DAKO),
and intensity was categorised as follows: 0 (no staining), 1þ
(incomplete circumferential staining), 2þ (complete circumfer-
ential staining), and 3þ (complete strong circumferential staining).
We regarded tumours with 45% of stained tumour cells to be
positive for either marker. Staining results were found to be very
similar among cores and in the event of a difference, we selected
the core with higher staining intensity provided that that tumour–
to–background signal was optimal. Staining criteria were reviewed
in a random subset by two pathologists (RLR, TCS) before scoring
all cases. All specimens were then analysed by a pathologist (RLR)
without the knowledge of clinical information.
Ki-67 and caspase-3 staining were scored using computerised
TMA images of individual tissue core images on a given slide (Slide
Scanner; Bacus Laboratories, Lombard, IL, USA), as previously
described (Sinicrope et al, 2007). The number of Ki-67- and caspase-
3-positive cells was determined, and mean and median values were
calculated. The caspase-3:Ki-67 ratio was determined by dividing
number of caspase-3 events by number of positive Ki-67 cells.
DNA MMR status
Defective DNA MMR was defined as absent expression of an MMR
protein by IHC and instability at the BAT 26 locus, as previously
described (Thibodeau et al, 1998; Parc et al, 2000; Garrity et al,
2004) for adjuvant study 91-46-53. For the other studies, MSI was
analysed as previously described (Thibodeau et al, 1998; Halling
et al, 1999) and tumours with high frequency instability (MSI-H,
X30% of the loci demonstrating MSI) (Boland et al, 1998; Halling
et al, 1999) were regarded as showing defective MMR, whereas the
others were categorized as showing intact MMR.
Statistical analysis
Chi-square tests were used to test for an association between
categorical variables and the Wilcoxon rank-sum test was used to
test for an association between a dichotomized variable and a
continuous variable. OS (censored at 8 years) was calculated as the
number of years from random assignment to the date of death or
last contact. DFS (censored at 5 years) was calculated as the number
of years from random assignment to the date of disease recurrence
or death. The distributions of OS and DFS were estimated using
Kaplan–Meier methodology. Univariate and multivariate Cox’s
proportional hazards models (Cox, 1972) were used to explore the
association of clinical and laboratory parameters with OS and DFS.
Graphical methods were used to examine whether the underlying
model assumptions were satisfied (e.g., proportional hazards)
(Grambsch and Terry, 1994). Statistical tests were two sided, with
Pp0.05 considered significant. P-values were not adjusted for
multiple comparisons. Statistical analyses were carried out using
SAS software (SAS Institute, Cary, NC, USA).
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Study population
Patient demographic data and clinicopathological features of the
colon carcinomas examined in this study are shown in Table 1.
Patients whose tumours were analysed for phospho-EGFR had a
median age of 64 years (mean 62.5, range 26–85). For EGPR,
median age was 64 years (mean 62, rage 30–83).
Phospho-EGFR, EGFR expression, and clinicopathological
features
Phospho-EGFR (Tyr-1173) expression was detected in 157 of 388
(40%) colon cancers (Table 1). Staining intensity was weak/
moderate (1þ and 2þ) and localised to the tumour cytoplasm
(Figure 1A). EGFR expression was analysed using the EGFR
pharmDx kit that was approved by the United States Food and
Drug Administration to assess patient eligibility for treatment
with anti-EGFR antibodies. We found that 214 of 361 (59%) colon
carcinomas examined showed EGFR plasma membrane staining
(1–3þ). Absent/weak/moderate EGFR intensity (0, 1þ,a n d2 þ)
w a sd e t e c t e di n3 0 1( 8 3 % )t u m o u r sa n dc o m p l e t es t r o n gc i r c u m f e r -
ential staining (3þ)w a sf o u n di n6 0( 1 7 % )( T a b l e1 ,F i g u r e1 B ) .
Phospho-EGFR expression did not correlate with the clinico-
pathological variables (Table 2). Colon cancers with strong EGFR
(3þ) vs other intensities (0–2þ) were significantly more likely to
be stage III (87 vs 73%; P¼0.03) (Table 2). EGFR intensity was
unrelated to patient age, gender, or tumour site (Table 2). We also
compared mean and median EGFR values with the clinicopatho-
logical variables. Poor/undifferentiated tumours had significantly
higher EGFR intensity compared with tumours with well/moderate
histological grade (P¼0.007) (data not shown). Expression of
EGFR and phospho-EGFR were not correlated in a patient subset
Table 1 Univariate survival analysis for p-EGFR and EGFR staining intensity
Parameter Number of patients 5-yr DFS % HR (95% CI) P-value
a 5-yr OS % HR (95% CI) P-value
a
Age (years)
p65 216 (56%) 65.6 — 0.40 72.2 — 0.18
465 172 (44%) 59.1 1.15 (0.83, 1.60) 68.6 1.24 (0.90, 1.72)
Gender
Female 185 (48%) 64.9 — 0.37 71.4 — 0.72
Male 203 (52%) 60.7 1.17 (0.84, 1.62) 69.9 1.06 (0.77, 1.46)
Tumour site
Distal 190 (49%) 61.9 — 0.60 71.1 — 0.78
Proximal 198 (51%) 63.5 0.92 (0.66, 1.27) 70.2 0.96 (0.69, 1.32)
Histological grade
Well/moderate 253 (65%) 65.1 — 0.10 74.3 — 0.038
Poor/undifferentiated 135 (35%) 58.3 1.32 (0.95, 1.85) 63.7 1.41 (1.02, 1.96)
Number of lymph nodes
0 77 (21%) 80.5 — o 0.0001 87.0 — o 0.0001
1–3 128 (35%) 66.7 1.78 (0.98, 3.24) 75.7 1.70 (0.95, 3.04)
43 158 (44%) 51.9 3.64 (2.05, 6.44) 60.1 3.70 (2.12, 6.46)
Tumour stage
Stage II 77 (20%) 80.5 — 0.0008 87.0 — 0.0008
Stage III 311 (80%) 58.3 2.43 (1.42, 4.15) 66.5 2.38 (1.41, 4.00)
MMR status
Intact MMR 327 (91%) 66.1 — 0.21 71.4 — 0.68
Defective MMR 33 (9%) 78.6 0.62 (0.29, 1.33) 84.6 0.88 (0.46, 1.67)
p-EGFR intensity
Absent (0) 231 (60%) 63.5 71.0
Weak (1+) 133 (34%) 63.0 1.01 (0.77, 1.32) 0.95 68.4 1.08 (0.83, 1.40) 0.55
Moderate (2+) 24 (6%) 54.2 79.2
p-EGFR intensity
Absent (0) 231 (60%) 63.5 — 0.99 71.0 — 0.60
Present (1+, 2+) 157 (40%) 61.6 1.0 (0. 71, 1.40) 70.1 1.09 (0.78, 1.53)
EGFR intensity
Absent (0) 147 (41%) 73.3 78.0
Weak (1+) 30 (8%) 66.7 1.21 (1.03, 1.41) 0.019 73.3 1.19 (1.02, 1.39) 0.028
Moderate (2+) 124 (34%) 66.5 72.4
Strong (3+) 60 (17%) 54.7 59.7
EGFR intensity
Absent/weak/moderate (0, 1+, 2+) 301 (83%) 69.8 — 0.022 75.2 — 0.047
Strong (3+) 60 (17%) 54.7 1.65 (1.07, 2.53) 59.7 1.55 (1.00, 2.39)
Abbreviations: CI, confidence interval; DFS, disease-free survival; EGFR, epidermal growth factor receptor; HR, hazard ratio; MMR, mismatch repair; OS, overall survival.
aScore
P-value stratified by adjuvant study.
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swherein both proteins were analysed (n¼190; P¼0.45). However,
32 of the 190 cases expressed phospho-EGFR but were negative for
EGFR. When these 32 cases were excluded, EGFR expression was
significantly correlated with phospho-EGFR (Po0.0001).
We found that 33 of 360 (9%) colon cancers showed defective
DNA MMR and 327 (91%) showed intact MMR (Table 1). Tumours
with defective MMR were significantly more likely to show
proximal location, poor/undifferentiated histology, and to be from
Figure 1 Immunohistochemical analysis of phospho-epidermal growth factor receptor (EGFR), EGFR, Ki-67, and caspase-3. (A) Colon carcinoma shows
phospho-EGFR staining in cytoplasm of tumour cells. Magnification:  10. (B) Colon carcinoma shows membranous EGFR staining intensity (2þ).
Magnification:  10. (C) Dual staining for caspase-3 (red) and Ki-67 (brown) allows apoptotic cells to be analysed in context of proliferating cells.
Magnification:  20. The color reproduction of this figure is available on the html full version of the manuscript.
Table 2 Association of EGFR
a and phospho-EGFR expression with clinicopathologic variables
Phospho-EGFR intensity (N¼388) EGFR intensity (N¼361)
Characteristic
Absent (0)
(N¼231)
Weak/Moderate (1+, 2+)
(N¼157) P-value
b
Other (0, 1+, 2+)
(N¼301)
Strong (3+)
(N¼60) P-value
b
Age (years)
p65 123 (53%) 93 (59%) 0.24 179 (60%) 29 (48%) 0.11
465 108 (47%) 64 (41%) 122 (40%) 31 (52%)
Gender
Female 107 (46%) 78 (50%) 0.52 142 (47%) 31 (52%) 0.52
Male 124 (54%) 79 (50%) 159 (53%) 29 (48%)
Tumour site
Proximal 111 (48%) 87 (55%) 0.15 134 (45%) 33 (55%) 0.14
Distal 120 (52%) 70 (45%) 167 (55%) 27 (45%)
Histological grade
c
1, 2 146 (63%) 107 (68%) 0.32 217 (72%) 37 (62%) 0.11
3, 4 85 (37%) 50 (32%) 84 (28%) 23 (38%)
Lymph nodes
0 41 (18%) 36 (26%) 0.14 80 (27%) 8 (13%) 0.09
1–3 86 (38%) 42 (30%) 142 (47%) 32 (53%)
43 98 (44%) 60 (44%) 79 (26%) 20 (33%)
TNM
II 41 (18%) 36 (23%) 0.21 80 (27%) 8 (13%) 0.03
III 190 (82%) 121 (77%) 221 (73%) 52 (87%)
MMR status
Intact MMR 189 (91%) 116 (88%) 0.38 273 (91%) 54 (90%) 0.81
Defective MMR 19 (9%) 16 (12%) 27 (9%) 6 (10%)
Ki-67
Median (range) 15.7 (0.0–82.0) 26.2 (0.6–89.2) 0.015
d,e 19.6 (0.0–89.2) 42.3 (1.7–85.8) 0.0002
d
Mean (s.d.) 24.3 (21.7) 31.4 (22.8) 25.6 (21.9) 39.0 (24.9)
Caspase-3
Median (range) 0.0 (0.0–20.0) 0.0 (0.0–46.0) 0.24
d,e 0.0 (0.0–35.0) 1.5 (0.0–46.0) 0.13
d
Mean (s.d.) 2.1 (3.6) 3.9 (7.8) 2.7 (5.1) 3.9 (7.4)
Caspase-3:Ki-67 ratio
Median (range) 0.0 (0.0–0.4) 0.0 (0.0–0.4) 0.54
d,f 0.0 (0.0–1.4) 0.0 (0.0–0.3) 0.31
d
Mean (s.d.) 0.0 (0.1) 0.0 (0.1) 0.0 (0.1) 0.0 (0.1)
Abbreviations: EGFR, epidermal growth factor receptor; MMR, mismatch repair.
aData are for membranous EGFR staining.
bChi-square P-value.
c1, 2 (well/moderate); 3, 4 (poor/
undifferentiated).
dWilcoxon’s rank-sum P-value.
e190 cases with p-EGFR and Ki67, caspase-3.
f189 cases with p-EGFR and caspase-3:Ki67 ratio.
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shown), as previously reported (Lothe et al, 1993; Thibodeau et al,
1993, 1998; Halling et al, 1999; Gryfe et al, 2000; Sinicrope et al,
2006a,b). Recently, elongation of a microsatellite repeat at the 50
UTR was found in colon cancers with defective MMR, but not in
those with intact MMR (Baranovskaya et al, 2009), and elongation of
this repeat was associated with downregulation of EGFR mRNA
levels. Accordingly, we compared EGFR expression with MMR
status in our study population. As a dichotomised variable, EGFR
intensity was unrelated to MMR status (Table 2). Mean and median
EGFR intensity were, however, increased in tumours with defective
vs intact MMR, but did not reach statistical significance (P¼0.065).
Association of phospho-EGFR and EGFR with cell
proliferation and apoptosis
Tumour growth rates are governed by the counterbalancing
processes of cell proliferation and apoptosis, as measured here
by Ki-67 and caspase-3 expression in a patient subset (n¼190)
(Figure 1C). Weak/moderate (1þ and 2þ) staining intensity (vs
absent) for phospho-EGFR was associated with a higher mean and
median number of Ki-67-positive tumour cells (P¼0.015)
(Table 2). Furthermore, tumours with strong (3þ) EGFR staining
intensity (vs other) had a higher mean and median number of
Ki-67-positive tumour cells (n¼361; P¼0.0002) (Table 2).
Tumours with poor/undifferentiated histology had a higher mean
and median number of Ki-67-positive tumour cells as compared
with tumours with well/moderate histologic grade (P¼0.0004)
(data not shown). Phospho-EGFR staining and strong EGFR
staining intensity were not significantly associated with caspase-3
expression nor with the caspase-3/ki-67 ratio (Table 2).
Association of phospho-EGFR and EGFR with patient
survival
The median duration of follow-up for patients who remain alive was
8 years. We analysed phospho-EGFR and EGFR staining intensity as
continuous variables. In a univariate analysis, patient tumours
expressing phospho-EGFR had similar DFS and OS survival rates
(Figure 2) as did tumours lacking phospho-EGFR (Table 1).
Increasing EGFR intensity was associated with significantly shorter
5-year DFS (hazard ratio (HR) (95% CI): 1.21 (1.03, 1.41), P¼0.019)
and OS (HR: 1.19 (1.02, 1.39), P¼0.028) rates (Table 1; Figure 3A
and B). We also analysed EGFR as a dichotomised variable and
compared tumours with absent/weak/moderate EGFR intensity (0,
1þ, and 2þ) vs strong (3þ) staining (Figure 3C and D). We
found that patients with tumours that showed strong staining had
significantly reduced 5-year DFS (HR (95% CI): 1.65 (1.07, 2.53),
P¼0.022) and OS (HR: 1.55 (1.00, 2.39), P¼0.47) rates (Table 1).
We then determined whether tumours expressing both EGFR and
phospho-EGFR (n¼158) had a poorer prognosis compared with
those with EGFR alone. However, no differences in survival were
found indicating that activation of EGFR Tyr-1173 does not further
affect prognosis in EGFR-expressing tumours. Neither Ki-67 nor
caspase-3 staining was prognostic. Lower tumour stage (II vs III)
and lesser number of metastatic lymph nodes were significantly
associated with more favourable DFS and OS rates (Table 1).
Furthermore, tumours with better differentiation showed more
favourable OS rates (Table 1). MMR status in tumours was not a
significant prognostic variable (n¼360) (Table 1).
In a multivariate analysis, EGFR intensity was analysed as a
continuous variable and was independently associated with shorter
DFS (HR: 1.18 (1.01, 1.38), P¼0.042) (Table 3). EGFR intensity was
also borderline significance for OS (HR: 1.15 (0.98, 1.34), P¼0.086)
in a model that included age, tumour stage, histological grade, and
MMR status (Table 3). The analysis of EGFR dichotomised as strong
(3þ) intensity vs other intensities showed similar results for DFS
(data not shown). Within this model, substituting the number of
metastatic lymph nodes for tumour stage yielded similar results for
EGFR intensity. Given the lack of association of phospho-EGFR and
clinical outcome by univariate analysis, it was not studied multi-
variately. However, we examined the prognosis of the subset of
tumours expressing both EGFR and phospho-EGFR compared with
EGFR alone. No differences were found between these tumour
subsets, thus suggesting that the EGFR activation status does not
confer additional prognostic information.
DISCUSSION
Although EGFR expression has been studied in colorectal cancers
(Lee et al, 2002; McKay et al, 2002; Spano et al, 2005), only limited
and inconsistent data are available concerning the EGFR activation
status in this malignancy. Furthermore, no studies have addressed
the prognostic effect of phospho-EGFR in colon cancer patients.
Accordingly, we analysed phospho-EGFR and EGFR expression in
a large series of stage II and III colon cancers from completed
5-fluorouracil-based adjuvant therapy trials (O’Connell et al, 2006).
Phospho-EGFR expression was detected in 157 of 388 (40%) colon
cancers using an antibody that recognises the major EGFR
autophosphorylation site at Tyr-1173. Tyr-1173 serves as a major
binding site for Shc, an adaptor protein involved in signalling
between EGFR and Ras (Okabayashi et al, 1994) and also as a
binding site for phosphatases (Agazie and Hayman, 2003), that
have an important role in modulating EGFR activity. Although the
expression of phospho-EGFR was not associated with clinico-
pathological variables, both phospho-EGFR and EGFR were
significantly associated with higher rates of cell proliferation,
but not apoptosis, consistent with unopposed cell proliferation.
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Figure 2 Univariate analysis of phospho-epidermal growth factor
receptor (EGFR) staining intensity and (A) disease-free survival (DFS) for
p-EGFR positive vs negative and (B) overall survival (OS) rates for p-EGFR
positive vs negative in stage II and III colon carcinomas (n¼388) from
patients treated in adjuvant therapy trials.
Phospho-EGFR in human colon cancers
RL Rego et al
169
British Journal of Cancer (2010) 102(1), 165–172 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sThe association of EGFR activation and expression with cell
proliferation likely reflects downstream signalling, including Ras
and ERK activation. ERK translocates to the nucleus and
phosphorylates transcription factors that regulate genes control-
ling cell proliferation, including cyclin D1 (Cesana et al, 2006)
that is overexpressed in 30–50% of colorectal carcinomas and is
associated with a poor prognosis (Arber et al, 1996; McKay et al,
2000). Phospho-EGFR was not prognostic in our study which is
concordant with the data obtained from non-small cell lung cancer
and breast cancer patients, wherein no associations with survival
were found (Cortas et al, 2007; Nieto et al, 2007). Although we
studied a major EGFR phosphorylation site, it is possible that
activation at other EGFR autophosphorylation sites may confer
prognostic information.
We detected membranous EGFR expression using the EGFR
pharmDx kit in 214 (59%) colon carcinomas. Potential mechanisms
for EGFR expression include its transcriptional upregulation,
decreased degradation, or gene amplification (Komuta et al,
1995; Shia et al, 2005). We found that strong EGFR intensity
was significantly associated with higher tumour stage (III vs II)
as compared with weaker EGFR intensity. EGFR protein expres-
sion was unrelated to tumour MMR status. This finding does
not support a recent study that found elongation of a dinucleotide
repeat in 55% of colon cancers with defective MMR, that was
associated with significantly reduced EGFR mRNA levels (Bar-
anovskaya et al, 2009). EGFR intensity as a continuous EGFR
variable was significantly associated with shorter DFS and OS rates
in a univariate analysis. EGFR was also a significant prognostic
variable for DFS and OS when dichotomized as strong vs other
intensity. In a recent study, strong (3þ) EGFR staining was
predictive of a high level of EGFR gene amplification (Hemmings
et al, 2009), although conflicting reports exist (Milano et al,
2008). In a multivariate analysis, we found that EGFR intensity
was independently associated with shorter DFS and was of
borderline statistical significance for OS. Some (Lee et al, 2002;
Resnick et al, 2004), but not other studies (McKay et al, 2002;
Spano et al, 2005), have shown an adverse prognostic effect for
EGFR expression in colorectal cancer patients. It is important to
note that we used the U.S. FDA-approved EGFR pharmDx kit with
its specific guidelines for EGFR scoring. Tumour stage, lymph
node metastases, and histological grade were prognostic variables
in our patient population. The lack of a survival advantage for
tumours with defective MMR status may be related to the sample
size and/or the observation that colon cancers with defective MMR
do not respond to adjuvant 5-fluorouracil, whereas those with
intact MMR receive a survival benefit from 5-fluorouracil
treatment (Ribic et al, 2003).
Our findings are similar to a study in high-risk breast cancer
patients where EGFR, but not phospho-EGFR, was an adverse
prognostic factor (Nieto et al, 2007). This study utilised the
phospho-EGFR Tyr 1086 antibody in breast cancers (Nieto et al,
2007) and reported a lack of association with EGFR, as was also
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Figure 3 Univariate analysis of continuous epidermal growth factor receptor (EGFR) staining intensity showing all the four categories and continuous
EGFR P-value for (A) disease-free (DFS) and (B) overall survival (OS) rates in patients with stage II and III colon carcinomas (n¼361) treated in adjuvant
therapy trials. The prognostic effect of EGFR intensity analysed as a dichotomised variable is also shown for (C) DFS and (D) OS in these patients (n¼361).
Table 3 Multivariate analysis of EGFR intensity as a continuous variable
Variable Hazard ratio (95% CI) P-value
a
Multivariate analysis for disease-free survival (N¼360)
EGFR intensity (1U increase) 1.18 (1.01, 1.38) 0.0415
Stage (III vs II) 1.99 (1.20, 3.30) 0.0040
Histological grade (3/4 vs 1/2) 1.44 (0.98, 2.13) 0.0683
Age (years) (4 65 vs p65) 0.86 (0.59, 1.25) 0.4325
MMR status (defective vs intact) 0.53 (0.24, 1.15) 0.0771
Multivariate analysis for overall survival (N¼360)
EGFR intensity (1U increase) 1.15 (0.98, 1.34) 0.0862
Stage (III vs II) 2.19 (1.31, 3.67) 0.0012
Histological grade (3/4 vs 1/2) 1.62 (1.11, 2.36) 0.0152
Age (years) (465 vs p65) 0.98 (0.68, 1.41) 0.9043
MMR status (defective vs intact) 0.69 (0.36, 1.34) 0.2540
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor;
MMR, mismatch repair.
aLikelihood ratio P-value.
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epithelial malignancies (Cunningham et al, 2005; Kong et al, 2006).
However, excluding cases with phospho-EGFR Tyr-1173 but
lacking EGFR staining resulted in a strong correlation between
these two markers in our patient subset. We also examined
whether the activation status of EGFR could alter the prognostic
effect of EGFR. We found that tumours co-expressing phospho-
EGFR and EGFR had a similar clinical outcome as those expressing
EGFR alone. Therefore, our finding that EGFR, but not phospho-
EGFR, is prognostic, suggests that the adverse effect on outcome is
not mediated by EGFR activation at Tyr-1173, but by its cross-talk
with other pathways.
Anti-EGFR therapies have been shown to inhibit EGFR
phosphorylation and to reduce proliferation in human colon
cancer cells and in tumour xenografts (Matar et al, 2004). Cell lines
with ligand-induced EGFR phosphorylation, regardless of EGFR
expression levels, show enhanced sensitivity to EGFR inhibitors
(Lynch et al, 2004; Paez et al, 2004). Although IHC analysis of
EGFR in colon cancers does not predict the efficacy of anti-EGFR
antibody therapy (Ciardiello and Tortora, 2003; Chung et al,
2005; Van Cutsem et al, 2007), the potential predictive impact of
phospho-EGFR expression for anti-EGFR antibodies in human
colorectal cancers remains unknown. Given that the majority of
patients in our adjuvant studies received 5-fluorouracil-based
therapy, we were unable to address its predictive effect. In a limited
number of metastatic colorectal carcinomas refractory to irinote-
can, higher levels of phospho-EGFR expression were associated
with better disease control in patients treated with cetuximab with
or without irinotecan (Personeni et al, 2005). Furthermore,
modulation of phospho-EGFR levels in skin biopsies during anti-
EGFR therapy were shown to predict efficacy and may therefore,
represent a potential surrogate biomarker (Agulnik et al, 2007).
Such issues are highly relevant to locoregionally advanced colon
cancers, as anti-EGFR antibodies are currently being studied in the
adjuvant setting in this patient population.
In conclusion, phospho-EGFR expression was detected in 40%
of stage II and III colon carcinomas. Both phospho-EGFR and
EGFR overexpression were associated with tumour cell hyper-
proliferation; however, only EGFR was associated with adverse
clinical outcome, thus suggesting that mechanisms other than
EGFR activation may underlie its prognostic effect. These data are
the first to analyze the prognostic effect of phospho-EGFR in
human colon cancer patients, yet further study to examine its
predictive utility for anti-EGFR therapy is warranted.
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